These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 16424796)

  • 1. Characterization of the in vivo and in vitro electrophysiological effects of the novel antiarrhythmic agent AZD7009 in atrial and ventricular tissue of the dog.
    Carlsson L; Chartier D; Nattel S
    J Cardiovasc Pharmacol; 2006 Jan; 47(1):123-32. PubMed ID: 16424796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electrophysiological and antiarrhythmic effects of the novel antiarrhythmic agent AZD7009: a comparison with azimilide and AVE0118 in the acutely dilated right atrium of the rabbit in vitro.
    Löfberg L; Jacobson I; Carlsson L
    Europace; 2006 Jul; 8(7):549-57. PubMed ID: 16798770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide in experimental models of torsades de pointes.
    Wu Y; Carlsson L; Liu T; Kowey PR; Yan GX
    J Cardiovasc Electrophysiol; 2005 Aug; 16(8):898-904. PubMed ID: 16101634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azimilide (NE-10064) can prolong or shorten the action potential duration in canine ventricular myocytes: dependence on blockade of K, Ca, and Na channels.
    Yao JA; Tseng GN
    J Cardiovasc Electrophysiol; 1997 Feb; 8(2):184-98. PubMed ID: 9048249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use-dependent effects of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization: block of delayed rectifier potassium and L-type calcium currents.
    Fermini B; Jurkiewicz NK; Jow B; Guinosso PJ; Baskin EP; Lynch JJ; Salata JJ
    J Cardiovasc Pharmacol; 1995 Aug; 26(2):259-71. PubMed ID: 7475051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electrophysiological effects of EGIS-7229, a new antiarrhythmic agent, in isolated mammalian and human cardiac tissues.
    Pankucsi C; Bányász T; Magyar J; Gyönös I; Kovács A; Varró A; Szénási G; Nánási PP
    Naunyn Schmiedebergs Arch Pharmacol; 1997 Mar; 355(3):398-405. PubMed ID: 9089672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azimilide causes reverse rate-dependent block while reducing both components of delayed-rectifier current in canine ventricular myocytes.
    Gintant GA
    J Cardiovasc Pharmacol; 1998 Jun; 31(6):945-53. PubMed ID: 9641481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional effects of the late sodium current inhibition by AZD7009 and lidocaine in rabbit isolated atrial and ventricular tissue and Purkinje fibre.
    Persson F; Andersson B; Duker G; Jacobson I; Carlsson L
    Eur J Pharmacol; 2007 Mar; 558(1-3):133-43. PubMed ID: 17198698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalol.
    Burashnikov A; Pourrier M; Gibson JK; Lynch JJ; Antzelevitch C
    Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):400-8. PubMed ID: 22322366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of azimilide on the muscarinic acetylcholine receptor-operated K+ current and experimental atrial fibrillation in guinea-pig hearts.
    Nishida A; Reien Y; Ogura T; Uemura H; Tamagawa M; Yabana H; Nakaya H
    J Pharmacol Sci; 2007 Nov; 105(3):229-39. PubMed ID: 17965539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of isoproterenol on the class III effect of azimilide in humans.
    Dorian P; Dunnmon P; Elstun L; Newman D
    J Cardiovasc Pharmacol Ther; 2002 Oct; 7(4):211-7. PubMed ID: 12490966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electrophysiological and antiarrhythmic effects of the novel I(Kur) channel blockers, S9947 and S20951, on left vs. right pig atrium in vivo in comparison with the I(Kr) blockers dofetilide, azimilide, d,l-sotalol and ibutilide.
    Knobloch K; Brendel J; Peukert S; Rosenstein B; Busch AE; Wirth KJ
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Nov; 366(5):482-7. PubMed ID: 12382079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A sodium channel blocker, pilsicainide, produces atrial post-repolarization refractoriness through the reduction of sodium channel availability.
    Fukuda K; Watanabe J; Yagi T; Wakayama Y; Nakano M; Kondo M; Kumagai K; Miura M; Shirato K; Shimokawa H
    Tohoku J Exp Med; 2011 Sep; 225(1):35-42. PubMed ID: 21869589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the rate-dependent properties of the class III antiarrhythmic agents azimilide (NE-10064) and E-4031: considerations on the mechanism of reverse rate-dependent action potential prolongation.
    Groh WJ; Gibson KJ; Maylie JG
    J Cardiovasc Electrophysiol; 1997 May; 8(5):529-36. PubMed ID: 9160229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome : direct evidence from intracellular recordings in the intact left ventricular wall.
    Yan GX; Wu Y; Liu T; Wang J; Marinchak RA; Kowey PR
    Circulation; 2001 Jun; 103(23):2851-6. PubMed ID: 11401944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The class III effect of azimilide is not associated with reverse use-dependence in open-chest dogs.
    Qi XQ; Newman D; Dorian P
    J Cardiovasc Pharmacol; 1999 Dec; 34(6):898-903. PubMed ID: 10598136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of intravenous azimilide on cardiac performance, fibrillation threshold, and hemodynamics in anesthetized dogs.
    Brooks RR; Finch SL
    Arzneimittelforschung; 2000 Jul; 50(7):597-605. PubMed ID: 10965415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electrophysiological characterization and antiarrhythmic efficacy of the mixed potassium channel-blocking antiarrhythmic agent AZ13395438 in vitro and in vivo.
    Jacobson I; Duker G; Florentzson M; Linhardt G; Lindhardt E; Nordkam AK; Åstrand A; Carlsson L
    J Cardiovasc Pharmacol Ther; 2013 May; 18(3):290-300. PubMed ID: 23307834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blocking characteristics of hERG, hNav1.5, and hKvLQT1/hminK after administration of the novel anti-arrhythmic compound AZD7009.
    Persson F; Carlsson L; Duker G; Jacobson I
    J Cardiovasc Electrophysiol; 2005 Mar; 16(3):329-41. PubMed ID: 15817095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined potassium and calcium channel antagonistic activities as a basis for neutral frequency dependent increase in action potential duration: comparison between BRL-32872 and azimilide.
    Bril A; Forest MC; Cheval B; Faivre JF
    Cardiovasc Res; 1998 Jan; 37(1):130-40. PubMed ID: 9539867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.